Jasper Therapeutics (JSPR, Financial) has been on analysts' radar lately. JMP Securities analyst Silvan Tuerkcan gave the stock a "buy" rating and projected it to reach $70.00. The Tuerkcan's optimistic outlook is due to Jasper's progress in its briquilimab program, which is advancing well in Phase III trials.
The randomized clinical trial BEACON Phase 1b/2a is one of Jasper's leading investigative programs. It aims to evaluate briquilimab as a treatment for CSU. Early data from this trial, expected in the first quarter of 2025, suggests that briquilimab may have a unique safety profile compared to other therapies. This targeted approach to c-Kit has demonstrated notable effectiveness in preclinical trials, drawing investor interest.
While Jasper has ceased enrollment and discontinued the LR-MDS program due to limited gains observed in hematopoiesis, management remains confident in Briquilimab's long-term safety profile. The recent Phase Ib/IIa trial, known as SPOTLIGHT, has provided further evidence of briquilimab's efficacy in mast cell-mediated disorders, with participants reporting symptom improvement in cases of chronic urticaria.
Jasper's strong cash position currently supports ongoing and upcoming projects through 2025, further boosting investor confidence. Another analyst from H.C. Wainwright also maintained a Buy rating with a slightly lower target price of $60.00.
Stock fundamentals could potentially drive Jasper upward if analysts and key opinion leaders continue to endorse briquilimab's effectiveness and the company's strategic focus on targeted treatments.
